On October 31, Guardant Health Inc. fell 5.26% in Regular Trading, trading at $176.28/share, with turnover of $137 million.
The clearest recent catalyst is a patent ruling: an appeal board rejected Guardant Health Inc.'s challenge to all 30 claims of a US patent tied to duplex sequencing, preserving a prior infringement outcome and reinforcing an existing legal overhang.
According to recent public developments, the ruling leaves intact a November 2023 jury verdict that Guardant Health Inc. willfully infringed the patent and supports more than $245.2 million in damages, accrued royalties and interest through May 2026. A separate final judgment issued in August also required a 6% royalty on sales of covered products and services from June 1 until patent expiry on March 15, 2033, plus quarterly accounting of US sales for 11 products and services. With earnings due on November 5, the litigation exposure appears to be pressuring sentiment despite earlier business positives such as FDA approval and favorable analyst initiation.
(The above content is based on publicly available market information, generated by a program or algorithm, and is intended solely as a stock movement alert. It does not constitute investment advice or a basis for trading decisions.)
Comments